Effects of Hypericum perforatum (St. John's wort) on hot flashes and quality of life in perimenopausal women: A randomized pilot trial

Menopause

Volumn 16, Issue 2, 2009, Pages 307-314

  Al Akoum, Mahéra ^a   Maunsell, Elizabeth ^a,b   Verreault, Rene ^a   Provencher, Louise ^a,b   Otis, Hélène ^b   Dodin, Sylvie ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Hot flashes; Hypericum perforatum; Menopause Specific Quality of Life questionnaire; Perimenopausal women; Pilot trial; Quality of life

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; PLACEBO;

ADULT; ANOREXIA; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CLIMACTERIUM; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; NAUSEA; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SWEATING; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; HYPERICUM; MIDDLE AGED; PERIMENOPAUSE; PHYTOTHERAPY; PILOT PROJECTS; PLANT EXTRACTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 67649319557     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818572a0     Document Type: Article

References (27)

1. Israel D, Youngkin EQ. Herbal therapies for perimenopausal and menopausal complaints. Pharmacotherapy 1997;17:970-984.
2. Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-2751.
3. Guay MP, Dragomir A, Pilon D, Moride Y, Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 2007;16:17-27.
4. Wright J. Use and Dangers of Alternative Medicines and Practices. Vancouver, BC, Canada: Angus Reid Group Inc, CTV/Angus Reid Group Poll 1997.
5. Singh SR, Levine MA. Natural health product use in Canada: analysis of the National Population Health Survey. Can J Clin Pharmacol 2006;13:e240-e250.
6. Rakovitch E, Pignol JP, Chartier C, et al. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death. Breast Cancer Res Treat 2005; 90:139-148.
7. Nedrow A, Miller J, Walker M, Nygren P, Huffman LH, Nelson HD. Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review. Arch Intern Med 2006;166:1453-1465.
8. Davis VL, Jayo MJ, Hardy ML, et al. Effects of black cohosh on mammary tumor development and progression in MMTV-neutransgenic mice. Paper presented at: 94th Annual Meeting of the American Association for Cancer Research; June 11-14, 2003; Washington, DC. Abstract 44.
9. Nelson HD, Vesco KK, Haney E, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057-2071.
10. Schulz V. Safety of St. John's wort extract compared to synthetic antidepressants. Phytomedicine 2006; 13:199-204.
11. Müller WE. Current St. John's wort research from mode of action to clinical efficacy. Pharmacol Res 2003;47:101-109.
12. Grube B, Walper A, Wheatley D. St. John's wort extract: efficacy for menopausal symptoms of psychological origin. Adv Ther 1999; 16:177-186.
13. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-597.
14. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
15. Whelan TJ, Goss PE, Ingle JN, et al. Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005; 23:6931-6940.
16. Di Maio M, Perrone F. Quality of life in elderly patients with cancer. Health Qual Life Outcomes 2003;1:44.
17. Wyrwich KW, Fihn SD, Tierney WM, Kroenke K, Babu AN, Wolinsky FD. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med 2003;18:196-202.
18. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. J Clin Epidemiol 1998;51:1171-1178.
19. Fillion L, Gelinas C, Simard S, Savard J, Gagnon P. Validation evidence for the French Canadian adaptation of the Multidimensional Fatigue Inventory as a measure of cancer-related fatigue. Cancer Nurs 2003; 26:143-154.
20. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988;41:313-321.
21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York, NY: Academic Press, 1969.
22. Maunsell E, Pogany L, Barrera M, Shaw AK, Speechley KN. Quality of life among long-term adolescent and adult survivors of childhood cancer. J Clin Oncol 2006;24:2527-2535.
23. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-383.
24. Clement K, Covertson CR, Johnson MJ, Dearing K. St. John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006;20:197-203.
25. Uebelhack R, Blohmer JU, Graubaum HJ, Busch R, Gruenwald J, Wernecke KD. Black cohosh and St. John's wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247-255.
26. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
27. Raeder MB, Bjelland I, Emil Vollset S, Steen VM. Obesity, dyslipide-mia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006;67:1974-1982.